Cyprotex (LSE: CRX) today announces that it has entered into a preclinical agreement with Avidex, the Oxford-based company that develops products for cancer and autoimmunity. The objective of the agreement is to optimise a successful candidate drug that inhibits the interaction of CD80 with CD28 on T cells and blocks T cell activation.
In this working relationship, Cyprotex will provide all the technologies and expertise necessary to evaluate and optimise the pre-clinical properties of Avidex's small molecule lead compounds.
Commenting on the collaboration, Dr David Leahy, Chief Scientific Officer of Cyprotex, said: "This project is recognition of the value of our integrated approach that addresses the major issues regarding the behaviour of drugs in the human body that will aid the selection of the best lead candidate. We are pleased to be working with Avidex and look forward to applying our extensive technology and expertise to the development of an exciting new product."
Dr David McGibney, Director of Drug Discovery & Development at Avidex, said: "We have selected Cyprotex to facilitate our development programme because we know they can provide the essential insight that is central to the continuation of our CD80 antagonist programme."
For further information:
Dr David Leahy, Chief Scientific Officer
Tel: +44 (0) 1625 505 100
Neill Mackenzie, Chief Business Officer
Tel: +44 (0) 1235 438600
For Cyprotex: Bankside Consultants Limited
Henry Harrison-Topham/ Heather Salmond
Tel: +44 (0) 20 7444 4140
For Avidex: HCC Defacto
Tel: +44 (0) 207 4963300